Pfizer asks U.S. to allow fourth COVID vaccine dose for seniors
WASHINGTON — Pfizer and its partner BioNTech asked U.S. regulators Tuesday to authorize an additional booster dose of their COVID-19 vaccine for seniors, saying data from Israel suggest older adults would benefit.
Currently the U.S. urges two primary shots followed months later by a booster dose for everyone age 12 and older. The new application seeks to add a fourth shot only for the over-65 population that has been hit hardest by the pandemic.
The Food and Drug Administration and the Centers for Disease Control would have to approve the request. If so, a key question would be how soon seniors would be advised to roll up their sleeves.
While authorities say the vaccinations continue to offer strong protection against severe illness, more vaccinated people have developed milder infections since the advent of the Omicron variant. With COVID-19 cases finally plummeting after the intense omicron surge, public health experts are starting to look ahead to what next steps might be needed — if a new variant crops up or, barring that, whether to try shoring up coronavirus protection in the fall at the same time people get flu vaccinations.
Throughout the pandemic, the U.S. has followed Europe by several weeks in waves of cases, and that may happen again, health experts warn.
Speaking to CBS’ “Face the Nation†on Sunday, Pfizer CEO Albert Bourla signaled the company’s plans.
“The protection that you are getting from the third, it is good enough, actually quite good for hospitalizations and deaths. It’s not that good against infections,†he said. “But we are just submitting those data to the FDA and then we will see what the experts also will say outside Pfizer.â€
The U.S. booster campaign was based on evidence that the shots’ effectiveness against infection was waning about six months after the last dose. Calls for a third shot grew once it became clear the vaccines weren’t as strong against the omicron mutant as they were against earlier versions of the virus.
Many scientists say the ultimate goal of vaccination is to prevent severe illness, not mild infections, and early CDC data show the shots still are doing a good job at that. During the omicron wave, effectiveness against hospitalization was 91% in people who had gotten their booster two months earlier, and 78% by the fourth month after that booster.
Pfizer based its new application on data from Israel, which already was offering a second booster to people age 60 and older and healthcare workers.
While some early data left unclear just how much benefit another shot offered — or for how long — Pfizer said Tuesday that an analysis of health records of more than 1.1 million Israeli seniors showed confirmed infections were two times lower and rates of severe illness were four times lower among those who got two boosters instead of just one.
Republican lawmakers asked California legislators to vote to end the emergency in a state Senate committee hearing Tuesday. The effort failed.
Pfizer also cited an ongoing study of healthcare workers that tracked a jump in virus-fighting antibodies after getting the additional booster.
In the U.S. so far, a fourth dose is recommended only for people with severely weakened immune systems, who need three doses to begin with for the best chance at any protection.
